Marinus Pharmaceuticals

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome

RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) announced that the U.S. Food and Drug Administration (FDA) recently granted orphan drug designation (ODD) to ganaxolone for the treatment of Lennox-Gastaut …

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome Read More

Ocugen

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the FDA recently granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment …

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis Read More